These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over

2024 has generally been an exceptionally good year for equities. The S&P 500 index hit another all-time high on Wednesday, and it is up a healthy 24% year to date.

As with any market, though, there are laggards. Here's a glance at the five worst-performing S&P 500 stocks thus far in 2024. Are any of these beaten-down businesses worthy of buying consideration at such levels?

A five-pack of veterans

The bottom five are (in order from steepest price decline to narrowest): Walgreens Boots Alliance (NASDAQ: WBA), Estée Lauder (NYSE: EL), Dollar Tree (NASDAQ: DLTR), Intel (NASDAQ: INTC), and Moderna (NASDAQ: MRNA). Here's the scorecard.

Data source: Slickcharts.com. Note: YTD price decrease as of market close Nov. 6.

The only repeat in the sector column is healthcare, indicating that those harrowing falls aren't industry-specific (many segments of healthcare are actually thriving these days). What we have here instead is a clutch of one-time high-flyers currently trying to cope with heavy pressure on their businesses.

Intel, the one-time leader in PC processors, has been hurt by declines in PC sales, and it keeps stumbling in its attempts to reinvent itself. Walgreens and Dollar Tree still run heavily brick-and-mortar retail operations in an age dominated by online shopping. Inflation's effect on consumer spending has also dinged the latter company.

As for the others, sentiment on Estée Lauder has been bruised by a lingering succession issue, not to mention an aggressive dividend cut. Meanwhile, investors are getting impatient for Moderna's next triumph after its Spikevax became a go-to vaccine during the COVID-19 pandemic's height.

One to consider

Of the quintet, the only stock I think might be a bargain now is Moderna, which continues to develop vaccines and medicines with the very promising mRNA-based technology foundational to Spikevax. Biotechs take time and resources to concoct new products, and I think Moderna will devise more cutting-edge medications and reward investors who are patient enough to wait.

Should you invest $1,000 in Walgreens Boots Alliance right now?

Before you buy stock in Walgreens Boots Alliance, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Walgreens Boots Alliance wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $857,383!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of November 4, 2024

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Intel and Moderna and recommends the following options: short November 2024 $24 calls on Intel. The Motley Fool has a disclosure policy.